Automated description from the Alliance of Genome Resources (Release 7.0.0)
Predicted to enable transmembrane transporter binding activity. Predicted to be involved in several processes, including negative regulation of mitotic cell cycle phase transition; positive regulation of potassium ion transport; and regulation of membrane depolarization. Predicted to act upstream of or within cell differentiation. Predicted to be located in cytosol; nucleus; and plasma membrane. Is expressed in several structures, including alimentary system; brain; cardiovascular system; genitourinary system; and sensory organ. Used to study scapuloperoneal myopathy. Human ortholog(s) of this gene implicated in Uruguay faciocardiomusculoskeletal syndrome; X-linked Emery-Dreifuss muscular dystrophy 6; reducing body myopathy 1A; and reducing body myopathy 1B. Orthologous to human FHL1 (four and a half LIM domains 1).